Exploratory secondary analysis of a phase 2 trial in IPF (n=276) and progressive pulmonary fibrosis (n=116): admilparant 60 mg vs placebo for 26 weeks changed serum biomarkers of epithelial injury, inflammation, fibrosis and collagen degradation.
Secondary analysisn = 392
Maher et al. Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA1 antagonism: exploratory analysis from a phase 2 trial of admilparant